Skip to main content
WHANIN PHARM CO.,LTD logo

WHANIN PHARM CO.,LTD — Investor Relations & Filings

Ticker · 016580 ISIN · KR7016580003 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2022-02-28 AGM Information
Country KR South Korea
Listing KO 016580

About WHANIN PHARM CO.,LTD

https://www.whanin.com/?lang=eng

WHANIN PHARM CO.,LTD. is a pharmaceutical company that develops, manufactures, and sells a range of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), with a particular focus on neuropsychiatric treatments such as anti-psychotics and CNS stimulants. In addition to its core CNS portfolio, Whanin Pharm's product line includes pharmaceuticals for the cardiovascular and gastrointestinal systems, antibiotics, and vitamin supplements. The company also provides development and manufacturing services for finished drug formulations.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hwanin Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items.
2022-02-28 Korean
유형자산취득결정(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure regarding the acquisition of tangible assets (land and buildings) by Hwanin Pharmaceutical. It details the transaction amount, purpose, and payment schedule as approved by the board. Since this is a specific corporate disclosure regarding asset acquisition that does not fit into financial reporting, M&A, or other specific categories, it falls under the general regulatory filing category.
2022-02-18 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Hwanin Pharmaceutical. It provides key financial highlights such as revenue, operating profit, and net income for the 4th quarter and the full year of 2021. It is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q4 2021
2022-02-09 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a report on the 'Compliance Program' (CP) performance and future plans for Hwanin Pharmaceutical. It details internal governance, anti-corruption systems (ISO 37001), and ethical management practices. Since this document describes the company's internal rules, board-level oversight (Audit Committee reports), and governance practices rather than financial results or specific regulatory filings, it falls under the Governance Information category.
2022-01-28 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Whanin Pharm Co., Ltd. (환인제약주식회사) for the third quarter of 2021 (2021.01.01-2021.09.30). It contains detailed financial statements, management discussion and analysis, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-12 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Hwanin Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the third quarter of 2021. It is a standard initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q3 2021
2021-11-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.